IO + IO = More to Know:: The Uncertain Potential for Combined Interventional and Immuno-Oncology
- PMID: 33506768
- PMCID: PMC8180312
- DOI: 10.1016/j.jvir.2020.09.027
IO + IO = More to Know:: The Uncertain Potential for Combined Interventional and Immuno-Oncology
Comment on
-
Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis.J Vasc Interv Radiol. 2021 Feb;32(2):187-195. doi: 10.1016/j.jvir.2020.09.014. Epub 2021 Jan 19. J Vasc Interv Radiol. 2021. PMID: 33353814
References
-
- Ochoa de Olza M, Navarro Rodrigo B, Zimmermann S, Coukos G. Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncol 2020;21:3419–430. - PubMed
-
- Zhan C, Ruohoniemi D, Shanbhogue KP, Wei J, Welling TH, Gu P, et al. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology. 2020;31:25–34. - PubMed
-
- Zheng J, Irani Z, Lawrence D, Flaherty K, Arellano RS. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series. J Vasc Interv Radiol 2019;29:1369–1375. - PubMed
-
- Levey AO, Elsayed M, Lawson DH, et al. Predictors of overall and progression-free survival in patients with ocular melanoma metasttic to the liver undergoing Y90 radioembolization. Cardiovasc Intervent Radiol 2020;43:254–263. - PubMed
-
- Ruohoniemi DM, Zhan C, Wei J, et al. Safety and effectiveness of Yttrium-90 radioembolization around the time of immune checkpoint inhibiotrs for unresectable hepatic metastases. J Vasc Interv Radiol 2020;31:1233–1241. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
